Bristol Myers Squibb Company $BMY Shares Sold by Capital Asset Advisory Services LLC

Capital Asset Advisory Services LLC cut its stake in Bristol Myers Squibb Company (NYSE:BMY) by 26.0% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 44,014 shares of the biopharmaceutical company’s stock after selling 15,461 shares during the period. Capital Asset Advisory Services LLC’s holdings in Bristol Myers Squibb were worth $2,603,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Swiss RE Ltd. acquired a new position in Bristol Myers Squibb during the fourth quarter worth $25,000. Darwin Wealth Management LLC purchased a new stake in Bristol Myers Squibb in the 2nd quarter valued at $25,000. Physician Wealth Advisors Inc. increased its stake in shares of Bristol Myers Squibb by 73.5% in the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 202 shares during the last quarter. Bayban acquired a new stake in shares of Bristol Myers Squibb in the 4th quarter worth $31,000. Finally, EQ Wealth Advisors LLC purchased a new position in shares of Bristol Myers Squibb during the 4th quarter worth $32,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently weighed in on BMY. Citigroup reissued a “neutral” rating on shares of Bristol Myers Squibb in a research report on Friday, May 1st. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Bristol Myers Squibb in a research note on Monday, March 23rd. UBS Group reiterated a “buy” rating on shares of Bristol Myers Squibb in a report on Thursday, May 28th. HSBC increased their price target on shares of Bristol Myers Squibb from $53.00 to $60.00 and gave the company a “hold” rating in a research note on Tuesday, March 17th. Finally, Cantor Fitzgerald raised their price target on shares of Bristol Myers Squibb from $45.00 to $54.00 and gave the stock a “neutral” rating in a report on Wednesday, April 8th. Eight research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $61.31.

Bristol Myers Squibb Stock Performance

NYSE BMY opened at $56.46 on Thursday. The stock has a market cap of $115.30 billion, a PE ratio of 15.86, a P/E/G ratio of 0.16 and a beta of 0.23. The company has a current ratio of 1.42, a quick ratio of 1.28 and a debt-to-equity ratio of 2.10. Bristol Myers Squibb Company has a twelve month low of $42.52 and a twelve month high of $62.89. The stock has a fifty day simple moving average of $56.95 and a 200-day simple moving average of $57.44.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.42 by $0.16. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The firm had revenue of $11.49 billion for the quarter, compared to analyst estimates of $10.93 billion. During the same period in the previous year, the firm earned $1.80 EPS. Bristol Myers Squibb’s revenue was up 2.6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Equities analysts anticipate that Bristol Myers Squibb Company will post 6.32 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd will be issued a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 4.5%. The ex-dividend date is Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio is currently 70.79%.

Key Stories Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb is continuing its collaboration with Arcus Biosciences on a kidney cancer trial, adding Arcus’s investigational drug casdatifan to Bristol Myers’ Phase 1/2 ROSETTA RCC-208 study. The update reinforces BMY’s pipeline activity in oncology, which could support long-term growth if the combination shows promise. Article Title
• Positive Sentiment: Several articles highlighted Bristol Myers Squibb as a value stock and a “trending” name, which can attract investor interest and reinforce the view that BMY may be attractive at its current valuation relative to peers. Article Title
• Positive Sentiment: Unusually heavy call-option activity suggests some traders are positioning for a rebound or a near-term move higher in Bristol Myers Squibb shares. Article Title
• Neutral Sentiment: Brisbane Myers Squibb was added to Russell 1000 Value Defensive and Defensive indexes while being removed from growth-oriented benchmarks. This mainly reflects a style reclassification rather than a direct business change, though it may influence fund flows and how investors view the stock. Article Title
• Negative Sentiment: Erste Group slightly lowered its FY2026 EPS estimate for BMY to $6.31 from $6.32, a small cut that nevertheless signals modestly softer expectations for earnings growth. Article Title
• Negative Sentiment: Concerns about proposed Medicare drug-price negotiation changes remain a headwind for Bristol Myers Squibb, since policy pressure on drug pricing could affect future revenue and margins. Article Title

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.